CIAM
PRQR icon

Caitong International Asset Management’s ProQR Therapeutics PRQR Stock Holding History

Caitong International Asset Management’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7 Sell
4
-119
-97% -$196 ﹤0.01% 2686
2026
Q1 		$199 Buy
+123
New +$202 ﹤0.01% 1880

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Caitong International Asset Management's PRQR Position: Q2 2026 in Review

Caitong International Asset Management reduced its ProQR Therapeutics (PRQR) stake by 97% in Q2 2026, selling an estimated $196 and leaving 4 shares worth $7. The position accounts for ﹤0.01% of the portfolio, ranked #2686.

Caitong International Asset Management first reported a position in PRQR in Q1 2026 and has held it in 2 quarters since. The position peaked at $199 in Q1 2026. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

  • Caitong International Asset Management held 4 shares of ProQR Therapeutics worth $7 as of Q2 2026.
  • Caitong International Asset Management sold 119 ProQR Therapeutics shares in Q2 2026, an estimated $196.
  • ProQR Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2686 holding.
  • Caitong International Asset Management first reported a position in ProQR Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Caitong International Asset Management's ProQR Therapeutics position peaked at $199 in Q1 2026.
  • 70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.